Fig. 3From: Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an exampleTumor uptake (calculated) and plasma PK (from literature) of 50 mg 89Zr-trastuzumab as a function of time. Tumor uptake (a) for a tumor without target expression (dashed line) and a clinically HER2-positive tumor (IHC3) (solid line). Plasma PK (b)Back to article page